1
|
Kolishovski G, Lamoureux A, Hale P, Richardson JE, Recla JM, Adesanya O, Simons A, Kunde-Ramamoorthy G, Bult CJ. The JAX Synteny Browser for mouse-human comparative genomics. Mamm Genome 2019; 30:353-361. [PMID: 31776723 PMCID: PMC6892358 DOI: 10.1007/s00335-019-09821-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 11/20/2019] [Indexed: 10/30/2022]
Abstract
Visualizing regions of conserved synteny between two genomes is supported by numerous software applications. However, none of the current applications allow researchers to select genome features to display or highlight in blocks of synteny based on the annotated biological properties of the features (e.g., type, function, and/or phenotype association). To address this usability gap, we developed an interactive web-based conserved synteny browser, The Jackson Laboratory (JAX) Synteny Browser. The browser allows researchers to highlight or selectively display genome features in the reference and/or the comparison genome according to the biological attributes of the features. Although the current implementation for the browser is limited to the reference genomes for the laboratory mouse and human, the software platform is intentionally genome agnostic. The JAX Synteny Browser software can be deployed for any two genomes where genome coordinates for syntenic blocks are defined and for which biological attributes of the features in one or both genomes are available in widely used standard bioinformatics file formats. The JAX Synteny Browser is available at: http://syntenybrowser.jax.org/. The code base is available from GitHub: https://github.com/TheJacksonLaboratory/syntenybrowser and is distributed under the Creative Commons Attribution license (CC BY).
Collapse
Affiliation(s)
- Georgi Kolishovski
- The Jackson Laboratory for Mammalian Genomics, Bar Harbor, ME, 04609, USA
| | - Anna Lamoureux
- The Jackson Laboratory for Mammalian Genomics, Bar Harbor, ME, 04609, USA
| | - Paul Hale
- The Jackson Laboratory for Mammalian Genomics, Bar Harbor, ME, 04609, USA
| | - Joel E Richardson
- The Jackson Laboratory for Mammalian Genomics, Bar Harbor, ME, 04609, USA
| | - Jill M Recla
- The Jackson Laboratory for Mammalian Genomics, Bar Harbor, ME, 04609, USA
| | - Omoluyi Adesanya
- The Jackson Laboratory for Mammalian Genomics, Bar Harbor, ME, 04609, USA
- Institute of Public Health, Washington University of St. Louis, St. Louis, MO, 63110, USA
| | - Al Simons
- The Jackson Laboratory for Mammalian Genomics, Bar Harbor, ME, 04609, USA
| | | | - Carol J Bult
- The Jackson Laboratory for Mammalian Genomics, Bar Harbor, ME, 04609, USA.
| |
Collapse
|
2
|
Abstract
Atherosclerosis is a chronic inflammatory disorder that is the underlying cause of most cardiovascular disease. Both cells of the vessel wall and cells of the immune system participate in atherogenesis. This process is heavily influenced by plasma lipoproteins, genetics, and the hemodynamics of the blood flow in the artery. A variety of small and large animal models have been used to study the atherogenic process. No model is ideal as each has its own advantages and limitations with respect to manipulation of the atherogenic process and modeling human atherosclerosis or lipoprotein profile. Useful large animal models include pigs, rabbits, and nonhuman primates. Due in large part to the relative ease of genetic manipulation and the relatively short time frame for the development of atherosclerosis, murine models are currently the most extensively used. Although not all aspects of murine atherosclerosis are identical to humans, studies using murine models have suggested potential biological processes and interactions that underlie this process. As it becomes clear that different factors may influence different stages of lesion development, the use of mouse models with the ability to turn on or delete proteins or cells in tissue specific and temporal manner will be very valuable.
Collapse
Affiliation(s)
- Godfrey S Getz
- Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
| | | |
Collapse
|
3
|
Döring Y, Noels H, Weber C. The Use of High-Throughput Technologies to Investigate Vascular Inflammation and Atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32:182-95. [DOI: 10.1161/atvbaha.111.232686] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The greatest challenge of scientific research is to understand the causes and consequences of disease. In recent years, great efforts have been devoted to unraveling the basic mechanisms of atherosclerosis (the underlying pathology of cardiovascular disease), which remains a major cause of morbidity and mortality worldwide. Because of the complex and multifactorial pathophysiology of cardiovascular disease, different research techniques have increasingly been combined to unravel genetic aspects, molecular pathways, and cellular functions involved in atherogenesis, vascular inflammation, and dyslipidemia to gain a multifaceted picture addressing this complexity. Thanks to the rapid evolution of high-throughput technologies, we are now able to generate large-scale data on the DNA, RNA, and protein levels. With the help of sophisticated computational tools, these data sets are integrated to enhance information extraction and are being increasingly used in a systems biology approach to model biological processes as interconnected and regulated networks. This review exemplifies the use of high-throughput technologies—such as genomics, transcriptomics, proteomics, and epigenomics—and systems biology to explore pathomechanisms of vascular inflammation and atherosclerosis.
Collapse
Affiliation(s)
- Yvonne Döring
- From the Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany (Y.D., C.W.); Institute for Molecular Cardiovascular Research, Rheinisch-Westfälische Technische Hochschule Aachen University, University Clinic Aachen, Aachen, Germany (H.N.); Munich Heart Alliance, Munich, Germany (C.W.); Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands (C.W.)
| | - Heidi Noels
- From the Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany (Y.D., C.W.); Institute for Molecular Cardiovascular Research, Rheinisch-Westfälische Technische Hochschule Aachen University, University Clinic Aachen, Aachen, Germany (H.N.); Munich Heart Alliance, Munich, Germany (C.W.); Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands (C.W.)
| | - Christian Weber
- From the Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany (Y.D., C.W.); Institute for Molecular Cardiovascular Research, Rheinisch-Westfälische Technische Hochschule Aachen University, University Clinic Aachen, Aachen, Germany (H.N.); Munich Heart Alliance, Munich, Germany (C.W.); Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands (C.W.)
| |
Collapse
|
4
|
Crooke RM, Graham MJ. Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia. ACTA ACUST UNITED AC 2011. [DOI: 10.2217/clp.11.59] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|